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The P2X7 receptor is an ionotropic ligand-gated purinergic 
receptor which is activated by extracellular ATP.1 Upon the 
application of physiological concentrations of this messenger, the 
P2X7 receptor acts as a cation selective ion channel, allowing the 
passage of Na+, K+ and Ca2+ through the plasma membrane, 
activating several signal transduction pathways for the correct 
function of the organism.2 However, when this receptor is 
exposed to high concentrations of ATP for a long period of time, 
in the high micromolar range, it induces the formation of a non-
selective large pore3 permeable to molecules up to 900 Da, which 
ultimately triggers cell apoptosis.4 
This ion channel is present in virtually all tissues of the body, 
being especially abundant in cells of hematopoietic lineage.5 Due 
to the widespread presence of the P2X7 receptor in the 
mammalian organism, its malfunction has been linked to a vast 
number of pathological conditions,6 including rheumatoid 
arthritis (RA), osteoporosis, 3DUNLQVRQ¶V GLVHDVH PXOWLSOH
sclerosis and cancer, among other relevant inflammatory, 
immune or musculoskeletal disorders.7 Taking into account that 
modulation of the P2X7 offers an ample possibility of therapeutic 
intervention, it is no surprise that in recent years several 
academic and non-academic groups have directed their research 
efforts to the development of potential P2X7 antagonists.8 
Resulting from this endeavour several structurally diverse 
small molecule inhibitors have come to light, placing the most 
promising ones into clinical trials (Figure 1). Unfortunately, all 
the candidates to date have failed in this process, resulting in a 
void in the P2X7 therapeutic pipeline. 
Figure 1. Structures of unsuccessful P2X7 clinical candidates. Two 
additional drugs (AFC-5128 and EVT-401, of undisclosed structures, also 
failed in clinical trials). 
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The adamantane scaffold, despite being widely used in medicinal chemistry, is not devoid of 
problems. In the recent years we have developed new polycyclic scaffolds as surrogates of the 
adamantane group with encouraging results in multiple targets. As an adamantane scaffold is a 
common structural feature in several P2X7 receptor antagonists, herein we report the synthesis 
and pharmacological evaluation of multiple replacement options of adamantane that maintain a 
good activity profile. Molecular modeling studies support the binding of the compounds to a site 
close to the central pore, rather than to the ATP-binding site and shed light on the structural 
requirements for novel P2X7 antagonists. 
2016 Elsevier Ltd. All rights reserved. 
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 One of the most promising chemical classes of P2X7 
antagonists is found in the adamantyl derivatives. Indeed, this 
class of compounds had its most auspicious example in the 
AZD9056 (Figure 1), which successfully progressed to phase II 
clinical trials; regrettably it failed to show significant efficacy in 
several inflammatory diseases (osteoarthritis, RA, COPD and 
&KURKQ¶V GLVHDVH.9 Unexpectedly after this failure, the 
adamantane core was not only not abandoned, but regained 
interest as a scaffold for P2X7
 
antagonists. Proof of this are the 
several patents filled by AstraZeneca, Lundbeck, Renovis and 
Abbot.10 Even more curious is the case of the academic groups 
that also resisted abandoning this scaffold, eagerly pursuing the 
preparation of adamantyl derivatives as P2X7
 
antagonists. Worth 
mentioning are the compounds developed by Lee et al.,11 such as 
2, and the C-2 disubstituted adamantanes developed by 
Battilocchio et al., such as 3.12 Despite the aforementioned 
combination of industry and academic efforts, modifying other 
moieties of the adamantyl derivatives has not met the expectation 
to overcome the drawbacks found in the past and send a 
compound to clinic. Surprisingly, little to no effort has been 
dedicated to exploring the possibilities of the adamantane moiety 
replacement. Among the few examples reported so far, we find 
only weakly active compounds such as norbornane 4,11 and 
cubane 5 (Figure 2).13 
Figure 2. Selected adamantane derivatives (1-3) with activity as P2X7 
receptor antagonists and examples of adamantane replacements (4-5). 
 
Taking into account the vast experience of our group in 
successfully replacing the adamantane with other tailor made 
polycyclic moieties and the capability of the aforementioned 
compounds to undergo structural modification we decided to 
explore this understudied path.14 
For this purpose, we envisaged four types of suitable scaffolds 
that may act as adamantane replacement for their assessment in 
terms of P2X7 receptor activity. The aliphatic polycyclic 
scaffolds were judiciously chosen taking into account several 
factors, first of all the maintenance of the desirable drug-like 
properties shown by the adamantane compounds. Secondly, the 
fact that they already proved as suitable adamantane 
replacements in our hands, yielding to potent compounds.14 
Finally, considering that when this work was carried out no 
crystal structures of the P2X7
 
were available,15 we aimed to 
explore the chemical space in the drug-binding site. To this aim, 
starting from the known nanomolar inhibitor 1, the bulkier 
substitution possibilities were embodied by I, its saturated 
analogue II, which display a similar shape index as adamantyl 
compounds (see below), and III, which exhibited a greater length 
alternative with restricted free rotation of the phenylhydrazine 
moiety. On the other hand, taking into account that smaller 
analogues of adamantane such as the norbornane and the cubane 
scaffolds exemplified by 4 and 5 led to poor antagonists, just one 
smaller scaffold (IV) was envisaged (Figure 3). 
 
Figure 3. Adamantane replacement scaffolds. R = C21+1+$U5¶ 1+$U. 
 
Diene 6, envisaged as a suitable precursor of I and II, was 
accessed through a concise 7-step synthetic route previously 
developed by our group.16 Upon treatment of 6 with thionyl 
chloride, the resulting acid chloride 7 was obtained and readily 
reacted with the desired hydrazine, to yield hydrazides 8-11 in 
good yields. The saturated analogues 12-14 were successfully 
prepared through a double bond reduction with hydrazide 
monohydrate under oxygen atmosphere.17 The compounds with 
the general structure III were easily accessed through the 
reaction of 1,3,5-cyclohepatriene with maleic anhydride, which 
furnished the polycyclic core in good yield.18 Upon reaction of 15 
with the corresponding phenylhydrazine, the compounds 16 - 18 
were dehydrated under Dean-Stark conditions to yield the 
cyclized adducts 19 ± 21 (Scheme 1). 
As the pharmacology trends for the already tested series I and 
II placed the 2-Cl substitution among the preferred one (see 
below), for the scaffold IV, only compound 24 was prepared. 
Hence, the hydrazide 24 was accessed from the known 
bisnoradamantane monoacid precursor19 and, paralleling the 
procedure for the preparation of derivatives I, was treated with 
thionyl chloride and readily reacted with 2-
chlorophenylhydrazine (Scheme 1). 
The structure of all new compounds was confirmed by 
accurate mass measurement, IR, 1H and 13C NMR spectroscopy. 
 
 
Scheme 1. Reagents and conditions: (a) SOCl2ǻ2 h, quantitative yield. (b) 
substituted phenylhydrazine hydrochloride, triethylamine, anh. THF, 
overnight, 92-99% yield. (c) hydrazine monohydrate, O2, ethanol, rt, 24 h, 
>95% yield. (d) substituted phenylhydrazine, ethanol, rt, overnight. (e) 
toluene, Dean-Stark, ǻ, 47-81% overall yield for d and e. R = see Table 1 for 
details. See supporting information for details. 
  
All new compounds were evaluated for their antagonistic 
HIIHFWV RQ ¶¶-O-(4-benzoylbenzoyl)-ATP (BzATP)-induced 
ethidium bromide uptake in human embryonic kidney 293 (HEK 
293) cells stably expressing the human P2X7 receptor, using 
compound KN62 as a positive control (Table 1).20 
In order to rationalize the results, the binding mode of all the 
compounds was analysed by docking in the extracellular domain 
of the homology models of the receptor hP2X7
 
and rP2X7, using 
AutoDock version 4.2.21 In agreement with the very recent 
crystal structures of five P2X7 antagonists in complex with a 
mammalian P2X7 receptor,15 our calculations supported the 
ability of the surrogate adamantane scaffolds to work as allosteric 
inhibitors. They fill a hydrophobic cavity close to the central pore 
of hP2X7, localized deeper in the receptor than the ATP binding 
site of hP2X7 (Figure 4A-B). The calculations also provided 
some clues about the observed structure-activity relationship 
(SAR). 
Regarding the aromatic moiety substitution, we took 
advantage of the SAR previously developed by Abbott around 
the adamantane derivative 1 that revealed electron-withdrawing 
substitutents in the ortho position of the phenyl ring as the 
preferred group.22 In fact, within our series, the ortho position 
clearly showed to be the preferred one for the activity (compare 9 
vs 10 and 13 vs 14, table 1). Interestingly, the introduction of a 
substituent in the para position was not only detrimental for the 
activity of the monosubstituted derivative (e.g., 10), but was able 
to abolish the benefitial effect of the ortho group (e.g., 11). This 
observation is explained by the steric clash of the para-
trifluoromethyl group with the residue Phe95 of the receptor that 
has been previously shown to play a key role by forming S-
stacking interactions with distinct inhibitors (Figure 4C).23 
Within this series, the most potent compound, 8 (IC50 = 96 
nM), bearing a chlorine atom in the ortho position, was nearly 9 
times less potent than its adamantane counterpart, 1 (IC50 = 11.5 
nM). Notwithstanding, 8 was much more potent than previously 
studied replacements for adamantane (e.g., 4 and 5). Moving 
from dienes I to alkanes II led to higher IC50 values (compare 8 
vs 12 and 9 vs 13), so full saturation of the structure is 
detrimental for the activity. This is rationalized as the dihedral 
angle formed by the amide and the aromatic ring, suffers a slight 
tilt in the saturated compound, compared to its more active 
unsaturated analogue (Figure 4D).   
As the hydrogen atom of the CONH group did not seem to 
play an essential role in the binding, we drew our attention to the 
conformationally restricted series III. Neither the unsubstituted 
phenyl derivative, 19, nor the ortho substituted analogues 20 and 
21, displayed significant activity, a fact that indicates that a 
degree of conformational freedom in the aromatic moiety is 
required when designing P2X7 inhibitors.  
Fully unexpectedly, taking into account the weak inhibitory 
activity displayed by known smaller replacement of adamantane, 
such as 4 and 5 (see above), compound 24 was revealed as the 
most potent analogue synthesized in this work, displaying an 
activity in the low nanomolar range (IC50 = 18 nM) which pairs 
the one displayed by its adamantane analogue 1 (IC50 = 11.5 nM). 
Strikingly, upon docking in the receptor, hydrazide 24 showed 
to adopt a completey different orientation (Figure 4E-F) than the 
one shown by its adamantane analogue 1 and 8, which parallels 
the adamantane compound in the binding site. Moreover, upon 
docking in the rP2X7 receptor, no unfavourable interactions were 
observed for 24, suggesting good antagonist potency. In view of 
the fact that several classes of inhibitors display significantly 
reduced the binding affinity in rP2X7 receptor, complicating 
further in vivo studies, our docking results further highlight the 
potential interest of bisnoradamantane derivatives as surrogates 
of adamantane. 
 
Table 1. P2X7 receptor antagonist activity of novel compounds.a 
Compound R IC50 (nM) 
8 2-Cl 96 ± 8 
9 2-CF3 132 ± 20 
10 4-CF3 <20%
b 
11 2-Cl, 4-CF3 1557 ± 500 
12 2-Cl 933 ± 156 
13 2-CF3 366 ± 37 
14 4-CF3 <20%
b 
19 H <20%
b 
20 2-Cl <20%
b 
21 2-F <20%
b 
24 2-Cl 18 ± 2 
KN-62 2-Cl 96 ± 11 
aExperiments were assessed in the ethidium accumulation assay using 
hP2X7R-expressing HEK293 cells. The IC50 values were obtained from 
concentration-response curves. Data are expressed as the means SD of at least 
3-6 experiments. bPercent inhibition at concentration 10 PM. 
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Figure 4. Docking of selected compounds and adamantane derivative 1 into 
the human P2X7 receptor. A. Compounds binding site in the whole 
extracellular domain. B. Compounds binding site in relation with the ATP 
binding site. C. Steric clash of the trifluoromethyl group of 10. D. 
Superposition of 8 (light blue) and 12 (grey) in the binding site. E. 
Bisnoradamantane derivative 24 in the receptor binding pocket. Position 95 
being Leu in the rP2X7 and Phe in the hP2X7. F. Superposition of 1 
(yellow), 8 (light blue) and 24 (purple) in their binding site. 
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To further explore the suitability as an adamantane 
replacement we predicted their physicochemical properties using 
DataWarrior.24 Of note, 24 and its isomer 1 displayed very 
similar physicochemical properties (Table 2). One of the main 
concerns when moving adamantane derivatives further into drug 
discovery programs is its easy metabolization by oxidation at the 
bridgehead positions. Taking into account that scaffold IV 
features two of the bridgehead positions substituted its 
metabolization by oxidation might be more difficult. 
 
Table 2. Relevant physicochemical properties for a representative example of 
each scaffold predicted by DataWarrior.a 
Compound 
(scaffold) 
M. W. 
(g/mol) 
cLogP H-
A 
H-
D 
PSA 
(Å2) 
SIb MFc sp3 
atoms 
1 304.82 4.32 3 2 41.13 0.52 0.53 10 
8 (I) 324.81 3.57 3 2 41.13 0.48 0.74 8 
12 (II) 328.84 4.12 3 3 41.13 0.48 0.74 12 
20 (III) 314.77 2.64 4 1 49.41 0.50 0.64 7 
24 (IV) 304.82 4.29 3 2 41.13 0.52 0.73 10 
aAll the series were predicted not to be mutagenic or tumorogenic agents. 
bShape index. cMolecular flexibility. 
In conclusion, eleven new compounds have been synthesized 
from four available polycyclic compounds as P2X7
 
antagonists. 
Several of these novel compounds displayed reasonable activity 
with 24, being the most potent with low nanomolar potency. To 
the best of our knowledge this is the first time, within the P2X7 
antagonist context, that the adamantane scaffold has been 
successfully replaced by a different polycyclic structure. On top 
of that, 24 is predicted to have physicochemical properties that 
parallel those of adamantane, reinforcing its suitability as a 
scaffold to develop drug-like compounds. Taken together, we can 
conclude that the smaller bisnoradamantane scaffold IV revealed 
as a very promising surrogate of adamantane regarding P2X7 
inhibition, in contrast to a hit-to-lead study reported by 
AstraZeneca that mentioned that no replacements for adamantane 
were found.25  
Research towards the development of novel polycyclic 
scaffolds to function as adamantane replacement and the 
exploration of further analogues of 24 are in progress to reach 
derivatives with optimum P2X7 activity and enhanced ADME 
properties. 
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